A bit about me
For me, market access is ultimately about patients. Contributing to bringing valuable treatments within their reach is what makes my work meaningful.
Career highlights
Maud joined Kintiga BeNeLux in September 2022 and has developed a strong focus on Market Access and Health Technology Assessment (HTA). Her journey with Kintiga began during her final year of the Pharmaceutical Sciences – Drug Development Master’s programme at KU Leuven, when she completed her Master’s thesis on the implementation of the EU HTA Regulation in collaboration with the team. Through this work, she developed an in-depth understanding of the regulation, including Joint Scientific Consultations (JSC) and Joint Clinical Assessments (JCA), and its implications for the pharmaceutical industry.
With dual Master’s degrees in Drug Development and Management & Policy in Healthcare, Maud combines a strong scientific background with experience in pricing, reimbursement and market access across Belgium (class 1, orphan, class 2B) and the Netherlands (GVS and lock). Her experience includes reimbursement strategy, risk assessment and the clinical and health-economic aspects of reimbursement dossiers across different therapeutic areas, including oncology, cardiovascular disease and orphan drugs.
Expertise
- EU HTAR strategy, readiness & implementation
- Pricing files Belgium
- Reimbursement Belgium and Netherlands
- Value story development & evidence translation
- Cross-functional strategic alignment (Medical, HEOR and Market Access)
- Scientific advice and KOL engagement
- Project management
Personal interests
Outside of work you will probably find me traveling around enjoying good food and wine or hiking in nature.